{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:20:48Z","timestamp":1792203648280,"version":"4.4.0"},"reference-count":13,"publisher":"Jaypee Brothers Medical Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.59556\/japi.73.0842","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T07:25:02Z","timestamp":1746084302000},"page":"39-46","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Efficacy of Biosimilar Insulin Glargine (Basaglar) in Indian Patients with Type 2 Diabetes Mellitus: Results from a Multicenter, Open-Label, Single-Arm, Phase 4 Trial (ABEX)"],"prefix":"10.59556","volume":"73","author":[{"given":"Banshi","family":"Saboo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Brahme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramesh","family":"Shamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indranil","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Spaepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"key":"key20250501072456_B1","doi-asserted-by":"crossref","first-page":"1047\u2013","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.","volume":"27:","author":"Wild","year":"2004;","journal-title":"Diabetes Care"},{"key":"key20250501072456_B2","doi-asserted-by":"crossref","first-page":"472\u2013","DOI":"10.2337\/dc15-1536","article-title":"Diabetes in Asia and the Pacific: Implications for the Global Epidemic.","volume":"39:","author":"Nanditha","year":"2016;","journal-title":"Diabetes Care"},{"key":"key20250501072456_B3","unstructured":"IDF. Diabetes Atlas Tenth edition 2021. (Accessed on 18 April 23). Retrieved from https:\/\/diabetesatlas.org\/atlas\/tenth-edition\/."},{"key":"key20250501072456_B4","doi-asserted-by":"crossref","first-page":"135\u2013","DOI":"10.1016\/j.pcd.2014.05.005","article-title":"Glycosylated hemoglobin level and number of oral antidiabetic drugs predict whether or not glycemic target is achieved in insulin-requiring type 2 diabetes.","volume":"9:","author":"Lin","year":"2015;","journal-title":"Prim Care Diabetes"},{"key":"key20250501072456_B5","doi-asserted-by":"crossref","first-page":"594\u2013","DOI":"10.4103\/2230-8210.113749","article-title":"Barriers and solutions to diabetes management: an Indian perspective.","volume":"17:","author":"Wangnoo","year":"2013;","journal-title":"Indian J Endocrinol Metab"},{"key":"key20250501072456_B6","doi-asserted-by":"crossref","first-page":"2753\u2013","DOI":"10.2337\/dci22-0034","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","volume":"45:","author":"Davies","year":"2022;","journal-title":"Diabetes Care"},{"key":"key20250501072456_B7","unstructured":"Pharmacy times. Pharmacy times. (2019, 27 November). FDA Approves Insulin Glargine Injection for Pediatric Patients with Diabetes. Retrieved from https:\/\/www.pharmacytimes.com\/view\/fda-approves-insulin-glargina-injection-for-pediatric-patients-with-diabetes."},{"key":"key20250501072456_B8","unstructured":"US Food and Drug Administration. (2015, December). BASAGLAR (insulin glargine injection), for subcutaneous use Initial U.S. Approval: 2000. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/205692lbl.pdf. 2015 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/205692Orig1s000TOC.cfm. Accessed on 18 April 2023."},{"key":"key20250501072456_B9","unstructured":"European Medicine Agency- Abasaglar (previously Abrasia). (2014, 14 October). Retrieved from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abasaglar-previously-abasria."},{"key":"key20250501072456_B10","doi-asserted-by":"crossref","first-page":"726\u2013","DOI":"10.1111\/dom.12496","article-title":"Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus\u00ae) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.","volume":"17:","author":"Blevins","year":"2015;","journal-title":"Diabetes Obes Metab"},{"key":"key20250501072456_B11","doi-asserted-by":"crossref","first-page":"734\u2013","DOI":"10.1111\/dom.12482","article-title":"Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus\u00ae) in patients with type 2 diabetes who were insulin-na\u00efve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).","volume":"17:","author":"Rosenstock","year":"2015;","journal-title":"Diabetes Obes Metab"},{"key":"key20250501072456_B12","doi-asserted-by":"crossref","first-page":"745\u2013","DOI":"10.1007\/s40261-019-00798-1","article-title":"Lilly Insulin Glargine Versus Lantus\u00ae in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study.","volume":"39:","author":"Mohan","year":"2019;","journal-title":"Clin Drug Investig"},{"key":"key20250501072456_B13","doi-asserted-by":"crossref","first-page":"189\u2013","DOI":"10.1007\/s13300-018-0549-3","article-title":"Lilly Insulin Glargine Versus Lantus(\u00ae) in Insulin-Na\u00efve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5).","volume":"10:","author":"Pollom","year":"2019;","journal-title":"Diabetes Ther"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T07:25:06Z","timestamp":1746084306000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-73-2-39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.59556\/japi.73.0842"],"URL":"https:\/\/doi.org\/10.59556\/japi.73.0842","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}